TGF beta receptor antagonists for selective signaling inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies to inhibit TGFβ signaling are non-selective and face challenges in targeting TGFβR-1 and TGFβR-2, which are crucial in various disorders including cancer, fibrosis, and inflammatory conditions, due to the complexity of the TGFβ signaling pathway and redundancy in ligand/receptor interactions.
Innovation Solution
Development of specific compounds, such as those of formula (I), which are TGFβR antagonists, capable of modulating the activity of TGFβR-1 and TGFβR-2, allowing for selective inhibition of these receptors to treat proliferative disorders and dysregulated apoptosis conditions like cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If non-selective inhibitors are used to block TGFβ signaling, then broad TGFβ pathway inhibition is achieved, but selectivity between TGFβR-1 and TGFβR-2 is lost
Solution Approach 1:
The patent segments the TGFβ receptor inhibition into two distinct binding sites: one for TGFβR-1 and another for TGFβR-2. The compound contains separate pharmacophoric elements that can independently interact with each receptor type, allowing selective inhibition of specific receptors while preserving others in the TGFβ pathway.
Solution Approach 2:
The patent introduces local quality differences through specific substituent patterns at defined positions in the compound structure. Different substituents (R1-R6) create localized chemical environments that confer preferential binding to either TGFβR-1 or TGFβR-2, enabling fine-tuned selectivity while maintaining overall pathway inhibition capability.
2Reliability
If the TGFβ signaling pathway is inhibited to treat cancer, then tumor progression is reduced, but the complexity of ligand/receptor interactions creates targeting challenges
Solution Approach 1:
The patent employs an intermediary compound structure that bridges the gap between multiple TGFβ ligands and their respective receptors. The compound acts as a mediator that can simultaneously or selectively engage TGFβR-1 and TGFβR-2, simplifying the complex ligand/receptor interactions into a single therapeutic agent that reliably inhibits tumor progression.
Solution Approach 2:
The patent creates a composite molecular structure combining multiple pharmacophoric elements within a single compound. This composite architecture integrates features necessary for binding to different TGFβ receptors, thereby managing the complexity of ligand/receptor interactions through a unified multi-functional molecule that provides reliable therapeutic efficacy.
3Reliability
If TGFβ signaling is blocked to treat fibrosis and inflammatory disorders, then tissue repair is modulated, but achieving selective receptor inhibition remains challenging
Solution Approach 1:
The patent utilizes parameter changes in the molecular structure (substituent types, positions, and configurations) to modulate receptor binding selectivity. By systematically varying chemical parameters at specific positions (R1-R6 substituents), the compound can be optimized to preferentially inhibit TGFβR-1 or TGFβR-2, achieving accurate receptor targeting while effectively treating fibrosis and inflammatory disorders.
Data Source
AI summary
The invention relates generally to compounds that modulate the activity of TGFBETA R-1 and TGFBETA R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.